Ranbaxy Rules Out "At-Risk" Lipitor Launch: Report

Law360, New York (January 26, 2005, 12:00 AM EST) -- Indian generic maker Ranbaxy Laboratories Ltd. won’t launch a generic version of Pfizer Inc.’s best-selling anti-cholesterol drug Lipitor “at risk” if it wins its patent challenge at the district-court level, according to a published report.

Chief Executive Brian Tempest told Reuters that he would await the outcome of any appeal before introducing a generic version of the cholesterol-lowering medicine in the United States.

“We wouldn't launch at risk. We are a conservative company. We will wait until the appeal at the federal level,” Tempest told the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.